Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LT-0002 is a preclinical-stage drug delivery system (DDS) platform developed by LTT Bio-Pharma. It utilizes a proprietary "Protein-technicization technology" designed to enhance the delivery, stability, and therapeutic profile of biologic drugs, specifically proteins. By modifying the structural or chemical properties of proteins, the technology aims to overcome common pharmacological hurdles such as rapid degradation or poor bioavailability. While the platform is part of LTT Bio-Pharma's active R&D pipeline, specific target indications or lead protein candidates associated with the LT-0002 designation have not been publicly specified in detail beyond its classification as a DDS for biologics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LT-0002.